T1	Participants 311 352	men with locally advanced prostate cancer
T2	Participants 568 615	patients with locally advanced prostate cancer.
T3	Participants 616 796	Patients with T3-4, N0/Nx, M0 prostate cancer or T1-2 disease with either prostate-specific antigen (PSA) of more than 40 μg/L or PSA of 20 to 40 μg/L plus Gleason score of 8 to 10
T4	Participants 1051 1089	One thousand two hundred five patients
